Cidara Therapeutics, Inc. Stock price

Equities

CDTX

US1717571079

Biotechnology & Medical Research

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.92 USD +9.25% Intraday chart for Cidara Therapeutics, Inc. +14.56% +15.87%
Sales 2023 * 57.85M Sales 2024 * 21.07M Capitalization 83.37M
Net income 2023 * -27M Net income 2024 * -56M EV / Sales 2023 * 1.44 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 3.96 x
P/E ratio 2023 *
-3 x
P/E ratio 2024 *
-1.6 x
Employees 73
Yield 2023 *
-
Yield 2024 *
-
Free-Float 92.47%
More Fundamentals * Assessed data
Dynamic Chart
North American Morning Briefing : Stocks Set for -2- DJ
North American Morning Briefing : Microsoft Kicks Off Big Tech Bonanza DJ
Cidara Therapeutics Says UK Regulator Approved Invasive Candidiasis Treatment MT
Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults CI
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q3 Revenue $12.7M MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults CI
Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023 CI
Transcript : Cidara Therapeutics, Inc. - Special Call
Cidara Shares Rally Premarket as J&J Moves Forward on Influenza Pact DJ
Cidara Therapeutics, Inc. Announces Janssen?S Election to Proceed Under Its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza CI
Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q2 Revenue $7.6M MT
More news

Latest transcript on Cidara Therapeutics, Inc.

1 day+9.25%
1 week+14.56%
Current month+30.04%
1 month+27.74%
3 months+13.58%
6 months-2.13%
Current year+15.87%
More quotes
1 week
0.72
Extreme 0.72
0.96
1 month
0.64
Extreme 0.64
0.96
Current year
0.63
Extreme 0.625
0.96
1 year
0.59
Extreme 0.593
1.48
3 years
0.40
Extreme 0.4
3.08
5 years
0.40
Extreme 0.4
4.45
10 years
0.40
Extreme 0.4
19.13
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 13-12-31
Director of Finance/CFO 51 21-08-31
Chief Tech/Sci/R&D Officer 57 12-12-31
Members of the board TitleAgeSince
Chairman 62 14-03-31
Director/Board Member 69 14-03-31
Chief Executive Officer 69 13-12-31
More insiders
Date Price Change Volume
24-03-28 0.92 +9.25% 1,509,045
24-03-27 0.8421 +13.80% 1,446,330
24-03-26 0.74 -0.86% 461,481
24-03-25 0.7464 -3.98% 499,849
24-03-22 0.7773 -3.21% 674,799

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company's primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples? potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.92 USD
Average target price
4.667 USD
Spread / Average Target
+407.25%
Consensus
  1. Stock
  2. Equities
  3. Stock Cidara Therapeutics, Inc. - Nasdaq